Illumina/$ILMN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Ticker

$ILMN
Sector
Primary listing

Employees

9,000

Illumina Metrics

BasicAdvanced
$15B
12.64
$7.91
1.37
-

What the Analysts think about Illumina

Analyst ratings (Buy, Hold, Sell) for Illumina stock.

Bulls say / Bears say

Illumina beat Q2 2025 estimates, posting $1.06 billion in revenue versus the $1.05 billion consensus and adjusted EPS of $1.19, well above the $1.01 forecast; non-GAAP operating margin climbed to 23.8%, and management raised full-year EPS guidance to $4.45–$4.55 (Reuters)
Illumina ranked fifth on TIME’s World’s Most Sustainable Companies list in 2024, underscoring its ESG leadership and innovations like a 90% cut in packaging for MiSeq i100 Series sequencers (TIME)
The June 2025 acquisition agreement for SomaLogic at $350 million (plus up to $75 million in milestones) accelerates Illumina’s multiomics push by adding proteomics expertise to its NGS platforms, creating a new high-margin revenue stream (PRNewswire)
Illumina’s 2025 revenue guidance was cut to $4.28 billion–$4.40 billion, below Wall Street’s consensus of $4.39 billion, reflecting weaker than expected demand for sequencing products amid industry funding constraints (Reuters)
China’s ban on imports of Illumina’s sequencing systems—which made up about 7% of 2024 revenue—resulted in narrowed 2025 non-GAAP EPS guidance of approximately $4.50 and a $100 million cost-reduction initiative to offset the lost sales (Reuters)
Political risks and rising competition are dampening Illumina’s growth. U.S. trade policies have led China to deem the company “unreliable” and NIH funding is capped, while Roche’s launch of a new sequencing platform intensifies pressure on Illumina’s market share (WSJ)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Illumina Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Illumina Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ILMN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs